| Date | Time | Source | Headline | Symbol | Company |
| 06/14/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:51PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:49PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:45PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:40PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:39PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:39PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:37PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 8:30PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:18PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:16PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:14PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:12PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:10PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:08PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:06PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:04PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:02PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 5:01PM | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 9:25AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 9:18AM | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/11/2024 | 9:15AM | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/03/2024 | 7:00AM | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 06/03/2024 | 7:00AM | Business Wire | Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/28/2024 | 6:08AM | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/22/2024 | 9:06AM | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/22/2024 | 7:01AM | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/13/2024 | 6:32AM | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/13/2024 | 6:31AM | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 05/10/2024 | 7:27AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |